Evidence map›Paper›PMID 25213768›Full record

ArticleExperimental & molecular medicine2014

Attenuation of airway inflammation by simvastatin and the implications for asthma treatment: is the jury still out?

Jing-Nan Liu, Dong-Hyeon Suh, Eun-Mi Yang, Seung-Ihm Lee, Hae-Sim Park, Yoo Seob Shin

Open access · goldAbstract read
In one paragraph

Article in Experimental & molecular medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Yangyin Qingre Huoxue Method in Traditional Chinese Medicine Ameliorates Atherosclerosis in ApoEEvidence-based complementary and alternative medicine : eCAM · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jing-Nan LiuDepartment of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.
Dong-Hyeon SuhDepartment of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.
Eun-Mi YangDepartment of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.
Seung-Ihm LeeDepartment of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.
Hae-Sim ParkDepartment of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.
Yoo Seob ShinDepartment of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.
Ajou University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although some studies have explained the immunomodulatory effects of statins, the exact mechanisms and the therapeutic significance of these molecules remain to be elucidated. This study not only evaluated the therapeutic potential and inhibitory mechanism of simvastatin in an ovalbumin (OVA)-specific asthma model in mice but also sought to clarify the future directions indicated by previous studies through a thorough review of the literature. BALB/c mice were sensitized to OVA and then administered three OVA challenges. On each challenge day, 40 mg kg(-1) simvastatin was injected before the challenge. The airway responsiveness, inflammatory cell composition, and cytokine levels in bronchoalveolar lavage (BAL) fluid were assessed after the final challenge, and the T cell composition and adhesion molecule expression in lung homogenates were determined. The administration of simvastatin decreased the airway responsiveness, the number of airway inflammatory cells, and the interleukin (IL)-4, IL-5 and IL-13 concentrations in BAL fluid compared with vehicle-treated mice (P<0.05). Histologically, the number of inflammatory cells and mucus-containing goblet cells in lung tissues also decreased in the simvastatin-treated mice. Flow cytometry showed that simvastatin treatment significantly reduced the percentage of pulmonary CD4(+) cells and the CD4(+)/CD8(+) T-cell ratio (P<0.05). Simvastatin treatment also decreased the expression of the vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 proteins, as measured in homogenized lung tissues (P<0.05) and human epithelial cells. The reduction in the T cell influx as a result of the decreased expression of cell adhesion molecules is one of the mechanisms by which simvastatin attenuates airway responsiveness and allergic inflammation. Rigorous review of the literature together with our findings suggested that simvastatin should be further developed as a potential therapeutic strategy for allergic asthma.

Indexed as

AnimalsAnti-Inflammatory AgentsAsthmaBronchoalveolar Lavage FluidCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInflammationInterleukinsLungMice, Inbred BALB CSimvastatinAnti-Inflammatory AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsInterleukinsSimvastatin

Identifiers

PMID25213768
PMCPMC4183942
OpenAlexW2003587993

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.